Clinical Trial Update: Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for Rituximab plus Bendamustine in follicular lymphoma patients who are refractory or relapsed after first-line rituxima…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)

Snippet

Sponsor: Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas | Conditions: Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line. | Phase 2 | Status: UNKNOWN